Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Accumulated Expenses (2019 - 2025)

Harmony Biosciences Holdings (HRMY) has disclosed Accumulated Expenses for 7 consecutive years, with $65.8 million as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses rose 2938.73% to $65.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $65.8 million through Dec 2025, up 2938.73% year-over-year, with the annual reading at $65.8 million for FY2025, 2938.73% up from the prior year.
  • Accumulated Expenses hit $65.8 million in Q4 2025 for Harmony Biosciences Holdings, up from $2.3 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $72.8 million in Q3 2023 to a low of $253000.0 in Q2 2022.
  • Historically, Accumulated Expenses has averaged $19.9 million across 5 years, with a median of $8.6 million in 2024.
  • Biggest five-year swings in Accumulated Expenses: crashed 97.86% in 2022 and later skyrocketed 25023.72% in 2023.
  • Year by year, Accumulated Expenses stood at $658000.0 in 2021, then soared by 399.39% to $3.3 million in 2022, then increased by 2.07% to $3.4 million in 2023, then crashed by 35.42% to $2.2 million in 2024, then soared by 2938.73% to $65.8 million in 2025.
  • Business Quant data shows Accumulated Expenses for HRMY at $65.8 million in Q4 2025, $2.3 million in Q3 2025, and $7.6 million in Q2 2025.